WO2016063246A1 - Crystalline form r of tedizolid phosphate - Google Patents

Crystalline form r of tedizolid phosphate Download PDF

Info

Publication number
WO2016063246A1
WO2016063246A1 PCT/IB2015/058159 IB2015058159W WO2016063246A1 WO 2016063246 A1 WO2016063246 A1 WO 2016063246A1 IB 2015058159 W IB2015058159 W IB 2015058159W WO 2016063246 A1 WO2016063246 A1 WO 2016063246A1
Authority
WO
WIPO (PCT)
Prior art keywords
tedizolid phosphate
crystalline form
acetate
solution
tedizolid
Prior art date
Application number
PCT/IB2015/058159
Other languages
French (fr)
Inventor
Anu Arya
Ram Thaimattam
Mohan Prasad
Original Assignee
Sun Pharmaceutical Industries Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sun Pharmaceutical Industries Limited filed Critical Sun Pharmaceutical Industries Limited
Publication of WO2016063246A1 publication Critical patent/WO2016063246A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole

Definitions

  • the present invention provides a crystalline form R of tedizolid phosphate, a process for its preparation, a pharmaceutical composition comprising it, and its use for the treatment of bacterial infections.
  • Tedizolid phosphate chemically is [(5i?)-3- ⁇ 3-fluoro-4-[6-(2-methyl-2H-tetrazol-5- yl)pyridin-3-yl]phenyl ⁇ -2-oxooxazolidin-5-yl]methyl hydrogen phosphate, represented by Formula I.
  • Tedizolid phosphate is indicated in adults for the treatment of acute bacterial skin and skin structure infections (ABSSSI) caused by designated susceptible bacteria.
  • U.S. Patent No. 8,426,389 discloses a crystalline form of tedizolid phosphate.
  • the present invention provides a crystalline form R of tedizolid phosphate, a process for its preparation, a pharmaceutical composition comprising it, and its use for the treatment of bacterial infections.
  • the crystalline form R of tedizolid phosphate can be formed under various crystallization conditions.
  • Figure 1 depicts an X-ray powder diffraction (XRPD) pattern of a crystalline form R of tedizolid phosphate.
  • Figure 2 depicts a Differential Scanning Calorimetry (DSC) thermogram of a crystalline form R of tedizolid phosphate.
  • DSC Differential Scanning Calorimetry
  • Figure 3 depicts an Infra-red (IR) absorption spectrum of a crystalline form R of tedizolid phosphate.
  • contacting refers to dissolving, slurrying, stirring, suspending, or combinations thereof.
  • a first aspect of the present invention provides a crystalline form R of tedizolid phosphate characterized by an X-ray powder diffraction (XRPD) pattern having peaks at d-spacings of about 5.2, 4.1, 3.9, and 3.8 A, and additional peaks at d-spacings of about 4.2, 4.0, 3.4, and 3.3 A.
  • XRPD X-ray powder diffraction
  • Table 1 provides the d-spacing values (A), the corresponding 2 ⁇ values, and the relative intensity (%) of crystalline form R of tedizolid phosphate.
  • the crystalline form R of tedizolid phosphate is further characterized by a differential scanning calorimetry (DSC) thermogram having endotherms at about 59.5°C and 225.0°C.
  • DSC differential scanning calorimetry
  • the crystalline form R of tedizolid phosphate is also characterized by an XRPD pattern substantially as depicted in Figure 1, a DSC thermogram substantially as depicted in Figure 2, or an IR absorption spectrum substantially as depicted in Figure 3.
  • a second aspect of the present invention provides a process for the preparation of a crystalline form R of tedizolid phosphate, comprising:
  • step a) adding a solvent selected from the group consisting of ketones, esters, nitriles, ethers, and mixtures thereof to the solution of step a) to obtain the crystalline form R of tedizolid phosphate.
  • Tedizolid phosphate used for the preparation of crystalline form R of tedizolid phosphate may be prepared according to the methods provided in the art, for example, U.S. Patent Nos. 7,816,379 or 8,604,209.
  • Tedizolid phosphate is contacted with orthophosphoric acid at a temperature of about 50°C to about 70°C, for example, of about 55°C to about 65°C.
  • ketones include acetone, butan-2-one, and isobutyl methyl ketone.
  • esters include methyl acetate, ethyl acetate, n-propyl acetate, isopropyl acetate, isobutyl acetate, n-butyl acetate, and tert-butyl acetate.
  • ethers include diethyl ether, ethyl methyl ether, diisopropyl ether, methyl tert-butyl ether, tetrahydrofuran, and 1,4-dioxane.
  • nitrile is acetonitrile.
  • the preparation of the crystalline form R of tedizolid phosphate is carried out at a temperature of about 40°C to about 80°C, for example, of about 45°C to about 70°C.
  • the preparation of the crystalline form R of tedizolid phosphate is carried out for about 1 hour to about 12 hours, for example, for about 2 hours to about 9 hours.
  • the crystalline form R of tedizolid phosphate may be isolated by filtration, decantation, extraction, distillation, evaporation, chromatography, precipitation, concentration, crystallization, centrifugation, or recrystallization, and dried under reduced pressure, by air drying or vacuum tray drying.
  • a third aspect of the present invention provides a pharmaceutical composition
  • a pharmaceutical composition comprising a crystalline form R of tedizolid phosphate and one or more pharmaceutically acceptable carriers, diluents, or excipients.
  • a fourth aspect of the present invention provides a method of treating bacterial infections comprising administering to a patient in need thereof a therapeutically effective amount of a crystalline form R of tedizolid phosphate.
  • the X-ray powder diffraction (XRPD) pattern was recorded using a PANalytical® X'pert PRO with X'celerator® as the detector.
  • the DSC thermogram was recorded on a Mettler-Toledo® 82 le.
  • the IR spectrum was recorded using a Perkin Elmer® instrument.
  • Tedizolid phosphate (0.30 g) was dissolved in orthophosphoric acid (1.0 mL) at 60°C to obtain a solution. Isobutyl methyl ketone (25 mL) was added to the solution. The resulting mixture was stirred at 60°C for 3 hours to obtain a precipitate. The precipitate was filtered, then dried under vacuum at 50°C for 6 hours to obtain the title compound.
  • Tedizolid phosphate (0.30 g) was dissolved in orthophosphoric acid (1.0 mL) at 60°C to obtain a solution. Methyl tert-butyl ether (25 mL) was added to the solution. The resulting mixture was stirred at 50°C for 3 hours to obtain a precipitate. The precipitate was filtered, then dried under vacuum at 50°C for 6 hours to obtain the title compound.
  • Tedizolid phosphate (0.30 g) was dissolved in orthophosphoric acid (1.0 mL) at
  • Tedizolid phosphate (0.30 g) was dissolved in orthophosphoric acid (1.5 mL) at 60°C to obtain a solution. Acetonitrile (25 mL) was added to the solution. The resulting mixture was stirred at 60°C for 3 hours to obtain a precipitate. The precipitate was filtered, then dried under vacuum at 50°C for 5.5 hours to obtain the title compound.
  • Tedizolid phosphate (0.30 g) was dissolved in orthophosphoric acid (1.0 mL) at 60°C to obtain a solution. Acetonitrile (25 mL) was added to the solution. The resulting mixture was stirred at 60°C for 3 hours to obtain a precipitate. The precipitate was filtered, then dried under vacuum at 50°C for 6 hours to obtain the title compound.
  • Tedizolid phosphate (0.30 g) was dissolved in orthophosphoric acid (1.0 mL) at 60°C to obtain a solution. Acetone (25 mL) was added to the solution. The resulting mixture was stirred at 60°C for 3 hours to obtain a precipitate. The precipitate was filtered, then dried under vacuum at 50°C for 6 hours to obtain the title compound.
  • Tedizolid phosphate (0.30 g) was dissolved in orthophosphoric acid (1.0 mL) at
  • Tedizolid phosphate (0.30 g) was dissolved in orthophosphoric acid (1.0 mL) at 60°C to obtain a solution. Ethyl acetate (25 mL) was added to the solution. The resulting mixture was stirred at 60°C for 3 hours to obtain a precipitate. The precipitate was filtered, then dried under vacuum at 50°C for 7 hours to obtain the title compound. Yield: 0.30 g
  • Tedizolid phosphate (0.30 g) was dissolved in orthophosphoric acid (1.0 mL) at 60°C to obtain a solution. Methyl acetate (25 mL) was added to the solution. The resulting mixture was stirred at 60°C for 3 hours to obtain a precipitate. The precipitate was filtered, then dried under vacuum at 50°C for 7 hours to obtain the title compound.
  • Tedizolid phosphate (0.30 g) was dissolved in orthophosphoric acid (1.0 mL) at 60°C to obtain a solution. Isopropyl acetate (25 mL) was added to the solution. The resulting mixture was stirred at 60°C for 3 hours to obtain a precipitate. The precipitate was filtered, then dried under vacuum at 50°C for 7 hours to obtain the title compound.
  • Tedizolid phosphate (0.30 g) was dissolved in orthophosphoric acid (1.0 mL) at
  • Tedizolid phosphate (0.30 g) was dissolved in orthophosphoric acid (1.0 mL) at 60°C to obtain a solution.
  • n-Butyl acetate 25 mL was added to the solution.
  • the resulting mixture was stirred at 60°C for 8 hours to obtain a precipitate.
  • the precipitate was filtered, then dried under vacuum at 50°C for 7 hours to obtain the title compound. Yield: 0.27 g
  • Tedizolid phosphate (0.50 g) was dissolved in orthophosphoric acid (1.5 mL) at 60°C to obtain a solution. Acetonitrile (35 mL) was added to the solution. The resulting mixture was stirred at 60°C for 3 hours to obtain a precipitate. The precipitate was filtered, then dried under vacuum at room temperature for 15 hours to obtain the title compound.
  • Tedizolid phosphate (0.30 g) was dissolved in orthophosphoric acid (1.0 mL) at
  • Tedizolid phosphate (5.0 g) was dissolved in orthophosphoric acid (13.0 mL) at 60°C to obtain a solution. Acetonitrile (250 mL) was added to the solution. The resulting mixture was stirred at 60°C for 3 hours to obtain a precipitate. The precipitate was filtered, then dried under vacuum at 60°C for 9 hours to obtain the title compound.
  • Tedizolid phosphate (5.0 g) was dissolved in orthophosphoric acid (13.0 mL) at 60°C to obtain a solution. Isobutyl methyl ketone (250 mL) was added to the solution. The resulting mixture was stirred at 60°C for 4 hours to obtain a precipitate. The precipitate was filtered, then dried under vacuum at 60°C for 14 hours to obtain the title compound.
  • Tedizolid phosphate (0.5 g) was dissolved in orthophosphoric acid (2.0 mL) at 60°C to obtain a solution. Acetonitrile (40 mL) was added to the solution. The resulting mixture was stirred at 60°C for 3 hours. The reaction mixture was cooled at 25°C to 30°C to obtain a precipitate. The precipitate was filtered, then dried under vacuum at 50°C for 9 hours to obtain the title compound.

Abstract

The present invention provides a crystalline form R of tedizolid phosphate, a process for its preparation, a pharmaceutical composition comprising it, and its use for the treatment of bacterial infections.

Description

CRYSTALLINE FORM R OF TEDIZOLID PHOSPHATE
Field of the Invention
The present invention provides a crystalline form R of tedizolid phosphate, a process for its preparation, a pharmaceutical composition comprising it, and its use for the treatment of bacterial infections.
Background of the Invention
Tedizolid phosphate chemically is [(5i?)-3-{3-fluoro-4-[6-(2-methyl-2H-tetrazol-5- yl)pyridin-3-yl]phenyl}-2-oxooxazolidin-5-yl]methyl hydrogen phosphate, represented by Formula I.
Figure imgf000002_0001
Formula I
Tedizolid phosphate is indicated in adults for the treatment of acute bacterial skin and skin structure infections (ABSSSI) caused by designated susceptible bacteria.
U.S. Patent Nos. 7,816,379 and 8,604,209 disclose processes for the preparation of tedizolid phosphate.
U.S. Patent No. 8,426,389 discloses a crystalline form of tedizolid phosphate.
There is a need in the art to develop a polymorphic form of tedizolid phosphate having improved physicochemical properties.
Summary of the Invention
The present invention provides a crystalline form R of tedizolid phosphate, a process for its preparation, a pharmaceutical composition comprising it, and its use for the treatment of bacterial infections.
The crystalline form R of tedizolid phosphate can be formed under various crystallization conditions. Brief Description of the Drawings
Figure 1 depicts an X-ray powder diffraction (XRPD) pattern of a crystalline form R of tedizolid phosphate.
Figure 2 depicts a Differential Scanning Calorimetry (DSC) thermogram of a crystalline form R of tedizolid phosphate.
Figure 3 depicts an Infra-red (IR) absorption spectrum of a crystalline form R of tedizolid phosphate.
Detailed Description of the Invention
The term "about," as used herein, refers to any value which lies within the range defined by a number up to ± 10% of the value .
The term "contacting," as used herein, refers to dissolving, slurrying, stirring, suspending, or combinations thereof.
A first aspect of the present invention provides a crystalline form R of tedizolid phosphate characterized by an X-ray powder diffraction (XRPD) pattern having peaks at d-spacings of about 5.2, 4.1, 3.9, and 3.8 A, and additional peaks at d-spacings of about 4.2, 4.0, 3.4, and 3.3 A.
Table 1 provides the d-spacing values (A), the corresponding 2Θ values, and the relative intensity (%) of crystalline form R of tedizolid phosphate.
Table 1
Figure imgf000003_0001
4.2 21.3 28.2
4.1 21.9 62.1
4.0 22.5 32.8
3.9 22.7 44.8
3.9 22.9 21.0
3.8 23.3 52.4
3.8 23.5 53.2
3.6 24.5 8.5
3.6 25.1 10.0
3.5 25.3 14.7
3.4 26.0 43.2
3.4 26.4 34.9
3.3 27.1 24.6
3.2 27.7 5.2
3.1 28.6 15.4
3.1 29.0 12.5
3.0 29.5 11.9
3.0 29.9 7.7
2.9 30.8 5.9
2.8 31.7 6.0
2.8 32.3 7.1
2.7 33.3 6.4
2.7 33.7 6.7
2.5 36.1 7.5
2.3 38.6 6.4
2.3 39.1 7.1
The crystalline form R of tedizolid phosphate is further characterized by a differential scanning calorimetry (DSC) thermogram having endotherms at about 59.5°C and 225.0°C.
The crystalline form R of tedizolid phosphate is also characterized by an XRPD pattern substantially as depicted in Figure 1, a DSC thermogram substantially as depicted in Figure 2, or an IR absorption spectrum substantially as depicted in Figure 3.
A second aspect of the present invention provides a process for the preparation of a crystalline form R of tedizolid phosphate, comprising:
a) contacting tedizolid phosphate with orthophosphoric acid to obtain a
solution; and b) adding a solvent selected from the group consisting of ketones, esters, nitriles, ethers, and mixtures thereof to the solution of step a) to obtain the crystalline form R of tedizolid phosphate.
Tedizolid phosphate used for the preparation of crystalline form R of tedizolid phosphate may be prepared according to the methods provided in the art, for example, U.S. Patent Nos. 7,816,379 or 8,604,209.
Tedizolid phosphate is contacted with orthophosphoric acid at a temperature of about 50°C to about 70°C, for example, of about 55°C to about 65°C.
Examples of ketones include acetone, butan-2-one, and isobutyl methyl ketone. Examples of esters include methyl acetate, ethyl acetate, n-propyl acetate, isopropyl acetate, isobutyl acetate, n-butyl acetate, and tert-butyl acetate.
Examples of ethers include diethyl ether, ethyl methyl ether, diisopropyl ether, methyl tert-butyl ether, tetrahydrofuran, and 1,4-dioxane.
An example of a nitrile is acetonitrile.
The preparation of the crystalline form R of tedizolid phosphate is carried out at a temperature of about 40°C to about 80°C, for example, of about 45°C to about 70°C.
The preparation of the crystalline form R of tedizolid phosphate is carried out for about 1 hour to about 12 hours, for example, for about 2 hours to about 9 hours.
The crystalline form R of tedizolid phosphate may be isolated by filtration, decantation, extraction, distillation, evaporation, chromatography, precipitation, concentration, crystallization, centrifugation, or recrystallization, and dried under reduced pressure, by air drying or vacuum tray drying.
A third aspect of the present invention provides a pharmaceutical composition comprising a crystalline form R of tedizolid phosphate and one or more pharmaceutically acceptable carriers, diluents, or excipients.
A fourth aspect of the present invention provides a method of treating bacterial infections comprising administering to a patient in need thereof a therapeutically effective amount of a crystalline form R of tedizolid phosphate. While the present invention has been described in terms of its specific aspects and embodiments, certain modifications and equivalents will be apparent to those skilled in the art, and are intended to be included within the scope of the present invention.
The following examples are for illustrative purposes only and should not be construed as limiting the scope of the invention in any way.
Methods
The X-ray powder diffraction (XRPD) pattern was recorded using a PANalytical® X'pert PRO with X'celerator® as the detector.
The DSC thermogram was recorded on a Mettler-Toledo® 82 le.
The IR spectrum was recorded using a Perkin Elmer® instrument.
Examples
Example 1 : Preparation of a crystalline form R of tedizolid phosphate
Tedizolid phosphate (0.30 g) was dissolved in orthophosphoric acid (1.0 mL) at 60°C to obtain a solution. Isobutyl methyl ketone (25 mL) was added to the solution. The resulting mixture was stirred at 60°C for 3 hours to obtain a precipitate. The precipitate was filtered, then dried under vacuum at 50°C for 6 hours to obtain the title compound.
Yield: 0.33 g
Example 2: Preparation of a crystalline form R of tedizolid phosphate
Tedizolid phosphate (0.30 g) was dissolved in orthophosphoric acid (1.0 mL) at 60°C to obtain a solution. Methyl tert-butyl ether (25 mL) was added to the solution. The resulting mixture was stirred at 50°C for 3 hours to obtain a precipitate. The precipitate was filtered, then dried under vacuum at 50°C for 6 hours to obtain the title compound.
Yield: 0.34 g
Example 3 : Preparation of a crystalline form R of tedizolid phosphate
Tedizolid phosphate (0.30 g) was dissolved in orthophosphoric acid (1.0 mL) at
60°C to obtain a solution. Butan-2-one (25 mL) was added to the solution. The resulting mixture was stirred at 60°C for 3 hours to obtain a precipitate. The precipitate was filtered, then dried under vacuum at 50°C for 7 hours to obtain the title compound.
Yield: 0.24 g Example 4: Preparation of a crystalline form R of tedizolid phosphate
Tedizolid phosphate (0.30 g) was dissolved in orthophosphoric acid (1.5 mL) at 60°C to obtain a solution. Acetonitrile (25 mL) was added to the solution. The resulting mixture was stirred at 60°C for 3 hours to obtain a precipitate. The precipitate was filtered, then dried under vacuum at 50°C for 5.5 hours to obtain the title compound.
Yield: 0.34 g
Example 5 : Preparation of a crystalline form R of tedizolid phosphate
Tedizolid phosphate (0.30 g) was dissolved in orthophosphoric acid (1.0 mL) at 60°C to obtain a solution. Acetonitrile (25 mL) was added to the solution. The resulting mixture was stirred at 60°C for 3 hours to obtain a precipitate. The precipitate was filtered, then dried under vacuum at 50°C for 6 hours to obtain the title compound.
Yield: 0.34 g
Example 6: Preparation of a crystalline form R of tedizolid phosphate
Tedizolid phosphate (0.30 g) was dissolved in orthophosphoric acid (1.0 mL) at 60°C to obtain a solution. Acetone (25 mL) was added to the solution. The resulting mixture was stirred at 60°C for 3 hours to obtain a precipitate. The precipitate was filtered, then dried under vacuum at 50°C for 6 hours to obtain the title compound.
Yield: 0.34 g
Example 7: Preparation of a crystalline form R of tedizolid phosphate
Tedizolid phosphate (0.30 g) was dissolved in orthophosphoric acid (1.0 mL) at
60°C to obtain a solution. Tert-butyl acetate (25 mL) was added to the solution. The resulting mixture was stirred at 60°C for 8 hours to obtain a precipitate. The precipitate was filtered, then dried under vacuum at 50°C for 6 hours to obtain the title compound.
Yield: 0.16 g
Example 8: Preparation of a crystalline form R of tedizolid phosphate
Tedizolid phosphate (0.30 g) was dissolved in orthophosphoric acid (1.0 mL) at 60°C to obtain a solution. Ethyl acetate (25 mL) was added to the solution. The resulting mixture was stirred at 60°C for 3 hours to obtain a precipitate. The precipitate was filtered, then dried under vacuum at 50°C for 7 hours to obtain the title compound. Yield: 0.30 g
Example 9: Preparation of a crystalline form R of tedizolid phosphate
Tedizolid phosphate (0.30 g) was dissolved in orthophosphoric acid (1.0 mL) at 60°C to obtain a solution. Methyl acetate (25 mL) was added to the solution. The resulting mixture was stirred at 60°C for 3 hours to obtain a precipitate. The precipitate was filtered, then dried under vacuum at 50°C for 7 hours to obtain the title compound.
Yield: 0.21 g
Example 10: Preparation of a crystalline form R of tedizolid phosphate
Tedizolid phosphate (0.30 g) was dissolved in orthophosphoric acid (1.0 mL) at 60°C to obtain a solution. Isopropyl acetate (25 mL) was added to the solution. The resulting mixture was stirred at 60°C for 3 hours to obtain a precipitate. The precipitate was filtered, then dried under vacuum at 50°C for 7 hours to obtain the title compound.
Yield: 0.26 g
Example 11 : Preparation of a crystalline form R of tedizolid phosphate
Tedizolid phosphate (0.30 g) was dissolved in orthophosphoric acid (1.0 mL) at
60°C to obtain a solution. Isobutyl acetate (25 mL) was added to the solution. The resulting mixture was stirred at 60°C for 8 hours to obtain a precipitate. The precipitate was filtered, then dried under vacuum at 50°C for 7 hours to obtain the title compound.
Yield: 0.30 g
Example 12: Preparation of a crystalline form R of tedizolid phosphate
Tedizolid phosphate (0.30 g) was dissolved in orthophosphoric acid (1.0 mL) at 60°C to obtain a solution. n-Butyl acetate (25 mL) was added to the solution. The resulting mixture was stirred at 60°C for 8 hours to obtain a precipitate. The precipitate was filtered, then dried under vacuum at 50°C for 7 hours to obtain the title compound. Yield: 0.27 g
Example 13: Preparation of a crystalline form R of tedizolid phosphate
Tedizolid phosphate (0.50 g) was dissolved in orthophosphoric acid (1.5 mL) at 60°C to obtain a solution. Acetonitrile (35 mL) was added to the solution. The resulting mixture was stirred at 60°C for 3 hours to obtain a precipitate. The precipitate was filtered, then dried under vacuum at room temperature for 15 hours to obtain the title compound.
Yield: 0.56 g
Example 14: Preparation of a crystalline form R of tedizolid phosphate
Tedizolid phosphate (0.30 g) was dissolved in orthophosphoric acid (1.0 mL) at
60°C to obtain a solution. Ethyl acetate (25 mL) was added to the solution. The resulting mixture was stirred at 60°C for 4.5 hours to obtain a precipitate. The precipitate was filtered, then dried under vacuum at 50°C for 7 hours to obtain the title compound.
Yield: 0.32 g
Example 15: Preparation of a crystalline form R of tedizolid phosphate
Tedizolid phosphate (5.0 g) was dissolved in orthophosphoric acid (13.0 mL) at 60°C to obtain a solution. Acetonitrile (250 mL) was added to the solution. The resulting mixture was stirred at 60°C for 3 hours to obtain a precipitate. The precipitate was filtered, then dried under vacuum at 60°C for 9 hours to obtain the title compound.
Yield: 5.73 g
Example 16: Preparation of a crystalline form R of tedizolid phosphate
Tedizolid phosphate (5.0 g) was dissolved in orthophosphoric acid (13.0 mL) at 60°C to obtain a solution. Isobutyl methyl ketone (250 mL) was added to the solution. The resulting mixture was stirred at 60°C for 4 hours to obtain a precipitate. The precipitate was filtered, then dried under vacuum at 60°C for 14 hours to obtain the title compound.
Yield: 5.88 g
Example 17: Preparation of a crystalline form R of tedizolid phosphate
Tedizolid phosphate (0.5 g) was dissolved in orthophosphoric acid (2.0 mL) at 60°C to obtain a solution. Acetonitrile (40 mL) was added to the solution. The resulting mixture was stirred at 60°C for 3 hours. The reaction mixture was cooled at 25°C to 30°C to obtain a precipitate. The precipitate was filtered, then dried under vacuum at 50°C for 9 hours to obtain the title compound.
Yield: 0.54 g

Claims

We Claim:
1. A crystalline form R of tedizolid phosphate characterized by an X-ray powder diffraction (XRPD) pattern having peaks at d-spacings of about 5.2, 4.1, 3.9, and 3.8 A. 2. The crystalline form R of tedizolid phosphate of claim 1, further characterized by an XRPD pattern having additional peaks at d-spacings of about 4.
2, 4.0, 3.4, and 3.3 A.
3. A crystalline form R of tedizolid phosphate characterized by a differential scanning calorimetry (DSC) thermogram having endotherms at about 59.5°C and 225.0°C.
4. A crystalline form R of tedizolid phosphate characterized by an XRPD pattern substantially as depicted in Figure 1, a DSC thermogram substantially as depicted in Figure 2, or an IR absorption spectrum substantially as depicted in Figure 3.
5. A process for the preparation of a crystalline form R of tedizolid phosphate, comprising:
a) contacting tedizolid phosphate with orthophosphoric acid to obtain a solution; and
b) adding a solvent selected from the group consisting of ketones, esters, nitriles, ethers, and mixtures thereof to the solution of step a) to obtain the crystalline form R of tedizolid phosphate.
6. The process according to claim 5, wherein tedizolid phosphate is contacted with orthophosphoric acid at a temperature of about 50°C to about 70°C.
7. The process according to claim 5, wherein the ketone is selected from the group consisting of acetone, butan-2-one, and isobutyl methyl ketone.
8. The process according to claim 5, wherein the ester is selected from the group consisting of methyl acetate, ethyl acetate, n-propyl acetate, isopropyl acetate, isobutyl acetate, n-butyl acetate and tert-butyl acetate.
9. The process according to claim 5, wherein the ether is selected from the group consisting of diethyl ether, ethyl methyl ether, diisopropyl ether, methyl fert-butyl ether, tetrahydrofuran, and 1,4-dioxane.
10. The process according to claim 5, wherein the nitrile is acetonitrile.
1 1. A pharmaceutical composition comprising a crystalline form R of tedizolid phosphate and one or more pharmaceutically acceptable carriers, diluents, or excipients.
12. A method of treating bacterial infections comprising administering to a patient in need thereof a therapeutically effective amount of the pharmaceutical composition comprising crystalline form R of tedizolid phosphate of claim 11.
PCT/IB2015/058159 2014-10-22 2015-10-22 Crystalline form r of tedizolid phosphate WO2016063246A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN3027DE2014 2014-10-22
IN3027/DEL/2014 2014-10-22

Publications (1)

Publication Number Publication Date
WO2016063246A1 true WO2016063246A1 (en) 2016-04-28

Family

ID=55760367

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2015/058159 WO2016063246A1 (en) 2014-10-22 2015-10-22 Crystalline form r of tedizolid phosphate

Country Status (1)

Country Link
WO (1) WO2016063246A1 (en)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3464985A (en) * 1967-08-18 1969-09-02 Bristol Myers Co 7 - (d - alpha - amino - (acetamidophenylacetamido))-cephalosporanic acids and derivatives thereof
US20050020488A1 (en) * 2001-08-24 2005-01-27 Leadbetter Michael R. Process for preparing glycopeptide phosphonate derivatives
US20100305069A1 (en) * 2009-05-28 2010-12-02 Trius Therapeutics Oxazolidinone containing dimer compounds, compositions and methods to make and use
WO2013093693A1 (en) * 2011-12-22 2013-06-27 Rinat Neuroscience Corp. Staphylococcus aureus specific antibodies and uses thereof
US20130310343A1 (en) * 2009-02-03 2013-11-21 Trius Therapeutics, Inc. Crystalline form of r)-3-(4-(2-(2-methyltetrazol-5-yl)pyridin- 5-yl)-3-fluorophenyl)-5-hydroxymethyl oxazolidin-2-one dihydrogen phosphate

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3464985A (en) * 1967-08-18 1969-09-02 Bristol Myers Co 7 - (d - alpha - amino - (acetamidophenylacetamido))-cephalosporanic acids and derivatives thereof
US20050020488A1 (en) * 2001-08-24 2005-01-27 Leadbetter Michael R. Process for preparing glycopeptide phosphonate derivatives
US20130310343A1 (en) * 2009-02-03 2013-11-21 Trius Therapeutics, Inc. Crystalline form of r)-3-(4-(2-(2-methyltetrazol-5-yl)pyridin- 5-yl)-3-fluorophenyl)-5-hydroxymethyl oxazolidin-2-one dihydrogen phosphate
US20100305069A1 (en) * 2009-05-28 2010-12-02 Trius Therapeutics Oxazolidinone containing dimer compounds, compositions and methods to make and use
WO2013093693A1 (en) * 2011-12-22 2013-06-27 Rinat Neuroscience Corp. Staphylococcus aureus specific antibodies and uses thereof

Similar Documents

Publication Publication Date Title
US20170240543A1 (en) Crystalline forms of palbociclib
EP3337485B1 (en) Crystalline forms of ibrutinib
EP3248983A1 (en) Crystal form a of obeticholic acid and preparation method therefor
WO1992001676A1 (en) Quinolonecarboxylic acid derivative
AU2016273899A1 (en) 7-{(3S,4S)-3-[(Cyclopropylamino)methyl]-4-fluoropyrrolidine-1-yl}-6-fluoro-1-(2-fluoroethyl)-8-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid crystal
CN115403521A (en) Synthesis method of lomefloxacin hydrochloride intermediate
CN106317114A (en) Method for preparing tedizolid phosphate
NO325656B1 (en) Anti-acid fast bacterial agents containing pyridone carboxylic acids as the active ingredient
US20060276463A1 (en) Pure levofloxacin hemihydrate and processes for preparation thereof
TWI808069B (en) New solid forms of [(1s)-1-[(2s,4r,5r)-5-(5-amino-2-oxo-thiazolo[4,5-d]pyrimidin-3-yl)-4-hydroxy-tetrahydrofuran-2-yl]propyl] acetate
WO2016075588A1 (en) Stable amorphous daclatasvir dihydrochloride
CN101100474B (en) Fluoroquinolone compound containing phosphate ester group and its preparation method and use
WO2012098501A1 (en) Febuxostat co-crystals
WO2016063246A1 (en) Crystalline form r of tedizolid phosphate
CN103113408B (en) A kind of novel method preparing phosphonomycin fosfomycin phenylethylamine calt
AU2015292050A1 (en) New polycrystalline form of tenofovir prodrug, and preparation method and application therefor
WO2017191620A1 (en) A crystalline form of a salt of sacubitril and a process of its preparation
CN113072564A (en) Heteroaromatic ring compound and application thereof
KR20180105450A (en) A Method of preparing Fimarsartan choline salt and hydrate thereof
JP2017514867A5 (en)
EP2448949A1 (en) Crystalline form of fosamprenavir calcium
CA2979121A1 (en) Stereoselective synthesis of enantiomers of 8-hydroxyquinoline derivati ves
CA3034535C (en) Novel salt of (r)-(1-methylpyrrolidine-3-yl)methyl(3'-chloro-4'-fluoro-[1,1'-biphenyl]-2-yl)carbamate and a crystal form thereof
WO2020049598A2 (en) Apalutamide polymorphs
CN101220055B (en) Method for preparing fluoroquinolone compounds containing phosphoric acid ester group

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 15852478

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 15852478

Country of ref document: EP

Kind code of ref document: A1